Stock Ratings / Health Care / HLF / earnings

NUS (62) ZSTK (31) ESYN (41) CAH (74) ⌘ Pro Terminal →

Herbalife Ltd. (HLF) Next Earnings Date & Expected ±7.9% Move

$12.93 -3.36% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Herbalife Ltd. (HLF) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HLF)Realized 20D OHLCV Swing Band: ±7.9%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±7.9% Swing Band

±$1.02 Expected Swing

MODEL EARNINGS SETUP GAUGE

HLF Quantitative Pre-Earnings Setup: 65/100

Trailing EPS: $2.18 • YoY Revenue Growth: 0.9%

Model Bullish Setup (65/100)Model Risk Weight (35/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$5.04B	$228.3M	$252.9M	77.9%
FY 2024	2024-12-31	$4.99B	$254.3M	$163.4M	77.9%
FY 2023	2023-12-31	$5.06B	$142.2M	$357.5M	77.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating HLF & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on HLF
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HLF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.11%📐 HORIZONTAL RANGE

2026-10-30O $13.01H $13.26L $12.83C $12.93VOL 1.52M

RES: $15.26SUP: $9.86SMA50: $12.71SMA200: $14.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HLF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HLF Butterfly Map → + Track HLF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-11.1%/yr Implied 5Y Growth

vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HLF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HLF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HLF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HLF)

Health Care Rank #136 of 1016 ⚔️ NUS vs HLF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HLF vs. NUS, ZSTK, ESYN, CAH)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Herbalife Ltd. (HLF) ranks #136 by composite RQD confidence (65/100, grade C) and #320 by equity capitalization ($1.36B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while HLF leads on capital efficiency and profitability with 34.4% ROIC and 77.9% gross margin. CAH currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with HLF at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HLF ACTIVE Herbalife Ltd.	C	65/100	5.9x	77.9%	34.4%	-3.36%	$1.36B	Benchmark Subject
NUS Nu Skin Enterprises Inc.	C	62/100	—	69.4%	6.7%	-1.47%	$228.3M	/nus-vs-hlf →
ZSTK ZeroStack Corp.	E	31/100	—	4.6%	-35.0%	-0.34%	$63.9M	/zstk-vs-hlf →
ESYN EnerSyn Global Inc.	D-	41/100	—	53.0%	-35.0%	+3.10%	$54.4M	/esyn-vs-hlf →
CAH Cardinal Health Inc.	B	74/100	37.2x	3.7%	29.7%	+2.59%	$58.14B	/cah-vs-hlf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001180262

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Herbalife Ltd. (HLF) reported GAAP revenue of $5.04B (+0.9% vs. FY2024 revenue of $4.99B , and -0.5% cumulative change since FY2023) , GAAP net income of $228.3M, operating cash flow of $333.3M, and free cash flow of $252.9M (+54.8% YoY). On the balance sheet, HLF closed FY2025 with $2.79B in total assets against $1.97B in total debt (Altman Z-Score: 2.39, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.04B	$228.3M	$333.3M	$252.9M	$2.79B	$1.97B
FY2024 (FY)	2024-12-31	$4.99B	$254.3M	$285.4M	$163.4M	$2.73B	$1.98B
FY2023 (FY)	2023-12-31	$5.06B	$142.2M	$357.5M	$357.5M	—	—

3. HLF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Herbalife Ltd. (NYSE: HLF) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $12.93 (-3.36% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, HLF ranks #136 in composite RQD confidence.

How does HLF compare to NUS and ZSTK in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), HLF carries a Roarable C (65/100 RQD), trailing P/E of 5.9x, gross margin of 77.9%, and ROIC of 34.4%. By comparison, NUS (Nu Skin Enterprises Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 6.7%, cap $228.3M) and ZSTK (ZeroStack Corp.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $63.9M). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while HLF leads on capital efficiency (34.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HLF?

Per HLF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001180262), Herbalife Ltd. generated $5.04B in revenue (+0.9% YoY), $228.3M in net income, and $252.9M in free cash flow against $2.79B in total assets and $1.97B in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HLF trading relative to its 50-day, 200-day, and 52-week technical levels?

HLF last traded at $12.93 (-3.36% on volume of 1,646,702 shares), positioning the stock +1.73% above its 50-day simple moving average ($12.71) and -7.71% below its 200-day simple moving average ($14.01). Across its 52-week range of $7.69 to $20.40, HLF sits at the 41.2% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($11.91 to $13.95).